Allan Dishington

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-2-one)

Kurt G. Pike, Bernard Barlaam, Elaine Cadogan et al. · Journal of Medicinal Chemistry · 2018 · 116 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Bernard Barlaam, Robert Casella, Justin Cidado et al. · Journal of Medicinal Chemistry · 2020 · 104 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

Sébastien L. Degorce, Bernard Barlaam, Elaine Cadogan et al. · Journal of Medicinal Chemistry · 2016 · 74 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology

Jeffrey W. Johannes, Lynsie Almeida, Bernard Barlaam et al. · ACS Medicinal Chemistry Letters · 2015 · 65 citations

Medicine, Oncology, Pharmacology +14

Rapid Generation of a High Quality Lead for Transforming Growth Factor-β (TGF-β) Type I Receptor (ALK5)

Frederick W. Goldberg, Richard A. Ward, Steven J. Powell et al. · Journal of Medicinal Chemistry · 2009 · 43 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17